Skip to main content

Table 1 Baseline characteristicsa

From: ABO and RhD blood group are not associated with mortality and morbidity in critically ill patients; a multicentre observational study of 29 512 patients

ABO group

Total

A

B

AB

O

P-valueb

N

29,512

12,969

3421

1416

11,706

 

ABO group current study, %

 

44

12

4.7

40

N.A.

ABO group in Sweden,% [24]

 

45

11

5.0

39

N.A.

Age, years

67 (25–85)

67 (25–85)

66 (24–84)

66 (23–85)

68 (25–85)

<0.001

Male sex

16,956 (58)

7406 (57)

1194 (58)

802 (57)

6754 (58)

0.516

SAPS 3 EMR,c %

18 (1.0–73)

18 (1.0–73)

18 (1.0–73)

18 (1.0–74)

19 (1.0–73)

0.762

Comorbidities, %

 Cancerd

9.0

9.2

8.5

8.1

9.0

0.591

 Heart failuree

5.8

5.4

5.4

7.0

6.2

0.083

 Blood malignancy

2.0

1.9

2.2

2.0

2.0

0.858

 Cirrhosis

2.0

1.9

2.1

2.0

1.8

0.803

 Immunosuppressionf

4.9

5.1

4.6

4.2

4.7

0.569

Admission route, %

 Emergency dept.

44

44

43

44

45

0.803

 Surgical theatre

11

11

12

12

11

0.757

 General ward

30

31

30

30

30

0.823

 Other ICU

3.7

3.7

4.0

3.1

3.6

0.110

 PACUg

3.6

3.6

3.5

3.3

3.8

0.858

 Missing data

6.8

6.8

7.3

7.0

6.8

0.686

Reason for admissionh, %

 Sepsisi

10

10

9.4

11

10

0.371

 Septic shock

4.6

4.8

3.9

4.2

4.7

0.097

 ARDS

19

19

19

19

19

0.757

 Covid–19

1.1

1.2

1.3

1.3

1.0

0.118

 Cardiac arrest

8.7

8.9

8.9

8.7

8.3

0.371

 Cardiovascularj

30

30

29

31

30

0.722

 Trauma

5.4

5.4

5.5

4.7

5.4

0.664

 Hepatic

5.2

5.2

5.4

4.8

5.1

0.819

 Abdominalk

23

23

23

22

23

0.849

 CNSl

39

39

40

41

38

0.268

 Renal

16

16

16

17

17

0.646

 Metabolic

17

17

17

16

17

0.687

Days in hospital before admission

0 (0–11)

0 (0–12)

0 (0–12)

0 (0–11)

0 (0–11)

0.675

Physiological parametersm

 Heart rate /min

100 (60–150)

100 (59–147)

100 (60–149)

100 (60–150)

100 (61–150)

0.014

 SBPn, mmHg

100 (52–162)

100 (54–160)

100 (50–165)

100 (55–163)

100 (50–164)

0.755

 Body temp., °C

37.0 (34.8–39.0)

37.0 (34.8–39.0)

37.0 (35.0–39.0)

37.0 (34.8–39.0)

37.0 (34.8–39.0)

0.658

 Leucocytes, x109/L

12 (4.0–28)

12 (3.8–27)

12 (4.1–28)

13 (4.0–29)

13 (4.1–28)

0.031

 Creatinine, μmol/L

94 (46–392)

94 (46–381)

94 (47–399)

92 (47–399)

95 (46–399)

0.604

 Bilirubin, μmol/L

10 (3.0–46)

10 (3.0–45)

10 (3.0–50)

10 (3.0–49)

10 (3.0–46)

0.241

 Platelet count, x109/L

211 (68–427)

212 (66–427)

208 (67–431)

213 (72–435)

211 (70–424)

0.368

 Blood pH

7.34 (7.01–7.49)

7.34 (7.01–7.49)

7.34 (7.01–7.48)

7.34 (7.03–7.49)

7.34 (7.01–7.49)

0.650

  1. aContinuous variables are presented as median (5–95 percentile) and numbers with %
  2. bChi-square test or Mann-Whitney-U test for differences between RhD status groups
  3. cEstimated mortality risk calibrated for Swedish conditions
  4. dSpread beyond regional lymph nodes
  5. eChronic heart failure NYHA IV
  6. fChronic steroid treatment corresponding to ≥0.3 mg/kg prednisolone/day,
  7. radiation or chemotherapy
  8. gPost-Anesthesia Care Unit
  9. hPatients may have multiple reasons for admission
  10. iAccording to Sepsis 2 definition
  11. jHypovolemia, cardiac shock, mixed shock, anaphylactic shock or arrhythmia
  12. kGastrointestinal bleeding, acute abdomen or pancreatitis
  13. lConvulsions, decreased consciousness, coma, delirium or intracranial volume effect
  14. mRegistered ± 90 min from admission
  15. nSystolic Blood Pressure
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us